Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels (Q36268387)

13 August 2017

1 reference

title

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels (English)

1 reference

13 August 2017

Katherine M Field

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

25

1 reference

13 August 2017

issue

10

1 reference

13 August 2017

page(s)

1365-1377

1 reference

Cardiovascular disease burden increases, NIH funding decreases

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Mortality by cause for eight regions of the world: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Inflammation and atherosclerosis: role of C-reactive protein in risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Statins and the acute-phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

C-reactive protein in the prediction of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Blood pressure, C-reactive protein, and risk of future cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Short-term effects of atorvastatin on C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

Coming of age of C-reactive protein: using inflammation markers in cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10.1365

10.1592/PHCO.2005.25.10.1365

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference